Zukanorm 50mg Tablet contains Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Vildagliptin enhances the incretin system by inhibiting the DPP-4 enzyme, thereby increasing the levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This mechanism results in improved pancreatic beta-cell function, increased insulin secretion in response to elevated blood glucose levels, and suppression of inappropriate glucagon release, contributing to better glycemic control. Zukanorm is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin or insulin when diet and exercise alone are insufficient to achieve target blood glucose levels. The recommended dose is 50mg administered orally once or twice daily, depending on the clinical scenario and patient response. Zukanorm is generally well tolerated, with a low risk of hypoglycemia when used as monotherapy. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose and renal function is recommended during therapy to optimize treatment outcomes and ensure patient safety.